The new research, published in Frontiers in Endocrinology, compared ultrasound-guided thermal ablation with conventional surgical resection in patients with small papillary thyroid carcinomas confined to the danger triangle. Papillary thyroid carcinoma is the most common thyroid malignancy, accounting for more than 80 percent of all thyroid cancers, and most of these tumors are indolent—slow-growing enough that treatment decisions hinge on balancing cure against harm. The danger triangle, however, raises the stakes: its cramped geometry complicates both surgery and ablation, and earlier studies had only short-term data to justify treating tumors there with heat rather than resection.

The study team reviewed 470 patients treated at two Chinese hospitals between September 2016 and April 2020 and, after applying strict criteria, analyzed 194 of them: 103 who received thermal ablation and 91 who had surgery. Because patients were not randomized, the researchers used propensity score matching to balance the two groups on age, sex, tumor size and volume, hormone levels, and precise anatomical distances—such as how far the tumor sat from the tracheoesophageal groove. After matching, 84 patients per group remained, and the groups were statistically indistinguishable at baseline.

The ablation technique itself is a study in precision. Performed under local anesthesia and real-time ultrasound guidance, the procedure uses either radiofrequency or microwave energy delivered through a thin electrode inserted through the isthmus of the gland. To protect the recurrent laryngeal nerve, trachea, and esophagus, the team continuously infused 5 percent dextrose solution around the tumor—a technique called hydrodissection that pushes vulnerable structures at least 5 millimeters away from the heat zone. Operators then used a low-power, moving-shot technique to destroy the tumor plus a margin of at least 3 millimeters, sparing the capsule where margins could not be extended safely. Immediate contrast-enhanced ultrasound confirmed that every treated lesion showed no residual blood flow, a 100 percent technical success rate.

Surgery, by contrast, followed Chinese national consensus guidelines and included prophylactic central neck dissection in all cases—a precaution reflecting concern that tumors abutting the posterior capsule carry a higher risk of hidden lymph node spread. Most surgical patients (88 percent) underwent lobectomy; the rest had total thyroidectomy, often driven by family history of thyroid cancer. The mean incision measured about 7.2 centimeters, compared with a 1-to-2-millimeter puncture for ablation.

After a median follow-up of roughly five and a half years in both groups, the oncologic results were strikingly similar. Overall disease progression occurred in 6.0 percent of the ablation group versus 4.8 percent of the surgery group—a difference with no statistical significance. Regional lymph node metastasis appeared in 1.2 percent of ablated patients and 3.6 percent of surgical patients; local tumor progression at the treatment site occurred in 3.6 percent versus 1.2 percent. Disease-free survival was 94 percent after ablation and 95.2 percent after surgery. No patient in either group developed distant metastasis. Notably, the ablation zone vanished completely in 94 percent of treated nodules over time, with smaller T1a tumors disappearing faster (a median of 24 months) than the larger T1b tumors (36 months).

The safety picture told a different story. Total complications were nearly three times more common after surgery: 16.7 percent versus 6.0 percent, a statistically significant difference. Every major complication occurred in the surgical group—four cases of permanent hoarseness from nerve injury and two cases of permanent hypoparathyroidism, both in patients who had total thyroidectomy. In the ablation group, the only complications were five cases of transient hoarseness, all of which resolved within six months without treatment. Among the smallest tumors (T1a, one centimeter or less), the safety gap widened further: 3.0 percent complication rate for ablation versus 15.3 percent for surgery. The authors caution that this subgroup finding is exploratory, given the small number of events.

Efficiency metrics favored ablation across the board. The average procedure took 23 minutes versus 82 minutes for surgery. Hospital stay averaged one day versus 3.3 days. Estimated blood loss was about 2 milliliters versus nearly 20. For elderly patients or those with comorbidities, the authors argue, such a short, low-risk pathway reduces not only perioperative danger but also healthcare resource use. And because ablation preserves the gland, patients avoid lifelong thyroid hormone replacement—a meaningful quality-of-life advantage that surgery cannot offer unless only one lobe is removed.

The study’s authors are careful about what the data do and do not show. Because no formal sample size calculation was performed, the similar outcomes cannot be formally interpreted as proof of equivalence or non-inferiority—a statistical distinction that matters. The retrospective design leaves room for unmeasured confounders such as patient preference and frailty. The ablation cohort mixed radiofrequency and microwave devices, and every ablation was performed by radiologists with more than a decade of experience, limiting generalizability to lower-volume centers. Differing follow-up schedules—ablation patients were imaged more often early on—could also bias event detection. Still, the authors note that progression rates rose only slightly from their earlier three-year report (from 4.4 to 6.0 percent in the ablation group), confirming durable oncologic stability.

The significance of the work lies in where it lands. The danger triangle has been a holdout region, where the proximity of nerve, trachea, and esophagus made many clinicians reluctant to ablate. By pairing hydrodissection with low-power, short-electrode techniques and rigorous ultrasound surveillance, this study shows that the same rules that made ablation safe elsewhere in the gland can be stretched into its most hostile corner. The authors call for multicenter randomized trials to confirm the findings, but for now the message is concrete: for carefully selected patients with small papillary thyroid carcinomas in the danger triangle, a needle, some dextrose, and a steady ultrasound-guided hand can match the oncologic results of surgery while sparing the voice, the parathyroids, and most of a hospital week.

Subject of Research: Long-term comparison of thermal ablation versus surgical resection for T1N0M0 papillary thyroid carcinoma in the thyroid danger triangle

Article Title: Long term (over five-year) outcomes of thermal ablation vs surgical resection for T1N0M0 papillary thyroid carcinoma in danger triangle: a propensity-matched dual-center study

Article References: Zhang, D., Chen, S., Yang, J., Qiu, Y., Zhao, Z., Tang, L., Hu, T., Yu, M.-A., & Wu, S. (2026). Long term (over five-year) outcomes of thermal ablation vs surgical resection for T1N0M0 papillary thyroid carcinoma in danger triangle: a propensity-matched dual-center study. Frontiers in Endocrinology, 17, Article 1887923. https://doi.org/10.3389/fendo.2026.1887923

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1887923

Keywords: papillary thyroid carcinoma, thermal ablation, radiofrequency ablation, thyroid danger triangle, propensity score matching, disease-free survival, recurrent laryngeal nerve, hydrodissection, thyroid surgery, minimally invasive treatment, lymph node metastasis, complication rates

The research, published open access in CVIR Oncology, tackles a question that has long haunted the field: how close is too close? Tumors metastatic to the spine and pelvis frequently press against the spinal cord, the cauda equina, peripheral nerves, and visceral organs, and the thermal energy that destroys tumor cells cannot distinguish friend from foe. The magnitude of unintended injury depends on the absolute temperature achieved, the duration of the thermal dose, the temperature sensitivity of neighboring tissues, and the distance between the at-risk structure and the edge of the ablation zone. Yet despite two decades of advances, the safe distance between a lesion and a vital structure had never been firmly established, leaving clinicians to rely on intuition and case-by-case judgment.

The study team, led by Carl Stokes and colleagues at the Mallinckrodt Institute of Radiology, analyzed 100 cryoablation procedures in 91 patients and 264 RFA procedures, all performed by attending musculoskeletal radiologists with five to twenty years of experience. Roughly four in five ablations targeted metastatic lesions, with the remainder treating primary tumors. The cryoablation cohort ranged from 5 to 82 years old, while RFA patients ranged from 4 to 89, underscoring how broadly these techniques are deployed across age groups and disease states. Lesions treated with cryoablation were predominantly osseous, most often in the pelvis or chest wall, while the overwhelming majority of RFA cases, 87.1 percent, involved the spine.

The technical arsenal documented in the study reads like a catalog of modern interventional radiology. Cryoablation was performed with the Visual-ICE system using a family of cryoprobes selected for target size and location, with standard two freeze-thaw cycles and CT images acquired every two to three minutes to track the growing ice ball. Skin warming and tissue displacement using carbon dioxide gas or hydrodissection fluid, either saline, iodinated contrast, or 5 percent dextrose, were the most common protective maneuvers. In select high-stakes cases near neural structures, transcranial electrical motor evoked potentials and somatosensory evoked potentials were monitored by certified neuroelectrophysiologic technologists with more than a decade of experience each, providing a real-time electrical readout of spinal cord and nerve function during the freeze.

RFA followed a different logic. Most procedures used a bipolar probe system under fluoroscopic guidance, with built-in thermocouples tracking tissue impedance and temperature throughout ablation. In 82.8 percent of RFA cases, patient biofeedback was the sole protective mechanism, meaning an awake patient reporting sensations of heat, burning, or tingling served as the early warning system. In the remaining 17.2 percent, clinicians added active measures such as carbon dioxide dissection or hydrodissection to physically push vulnerable structures out of harm’s way. The distinction between passive protection, which monitors for impending injury, and active protection, which physically prevents it, proved central to the study’s conclusions.

The numbers tell a compelling story. Thermoprotective techniques measurably widened the safety margin in every anatomic category. For cryoablation lesions near the spinal cord or cauda equina, the mean distance increased from 1.0 centimeter to 1.3 centimeters after protection. Near peripheral nerves, the mean distance grew from 0.9 to 1.3 centimeters. The most dramatic gains appeared near visceral structures such as bowel and bladder, where the average distance of a mere 0.3 centimeters, essentially touching, was expanded to 1.3 centimeters. In the RFA cohort, lesions near the spinal canal went from a mean of 0.4 centimeters to 0.9 centimeters, and lesions adjacent to peripheral nerves more than tripled their separation, from 0.4 to 1.2 centimeters.

Complications, when they occurred, were mostly transient or self-limited. In the cryoablation group, the most common event was grade-2 transient weakness in two patients, followed by one case each of grade-3 hypertensive urgency and grade-4 hemorrhage during ablation of a chest wall hemangiopericytoma, which required emergency embolization of an intercostal artery. The single neurological event involved transient left leg weakness that resolved within 24 hours without intervention, occurring in a lesion that remained less than one centimeter from the thoracic spinal cord even after protection. In the RFA group, complications included arrhythmia, nausea, post-procedural pain requiring hospital admission, hypertensive urgency, and one venous spinal cord infarction, all in patients receiving passive protection only. Zero complications were recorded in the 44 patients who received active thermoprotection during RFA.

Two risk patterns emerged with particular clarity. First, procedural duration correlated with complications: patients who experienced adverse events averaged 217.5 minutes of cryoablation time and 137.4 minutes of RFA time, longer than cohort norms, likely reflecting case complexity. Second, the number of cryoprobes used proved a striking predictor. Complicated cases averaged 13.5 probes compared with a cohort average of 4.1, more than a threefold difference, confirming a trend previously described in the literature. Notably, concomitant cementoplasty, biopsy, and neurophysiologic monitoring added no meaningful procedure time or complication risk, and the exothermic polymerization of bone cement was insufficient to cause tumor necrosis at the bone-cement interface, corroborating earlier work.

The study’s most consequential message is a reframing of contraindications. Because no complications occurred in RFA with active protection, and only one transient deficit appeared in cryoablation even when lesions sat within a centimeter of the spinal cord, the authors argue that thermoprotection itself, rather than strict adherence to any distance threshold, is the dominant factor in mitigating risk. The clinical significance of adding a centimeter of separation remains uncertain in absolute terms, but the pattern across hundreds of cases, including 15 extremity cryoablations near the skin, a site where prior studies report skin burn rates around 2.8 percent, suggests protective techniques work. No dermal complications, infections, or superficial burns occurred in this cohort.

The authors are candid about limitations: the retrospective single-institution design, the low event rate that prevented statistically powered multivariate analysis, a single reader for image review, and the absence of recorded time spent on protective maneuvers. Still, the scale of the series, spanning more than a decade and hundreds of procedures, lends weight to its central recommendation: prophylactic use of active and passive thermoprotection whenever critical structures are at risk, and a firm rejection of proximity alone as a reason to deny patients ablation. For the growing number of patients with painful musculoskeletal tumors, many of them metastatic and with limited options, the message is that the no-go zones around the spine and nerves may be far smaller than once feared, provided the right shields are in place.

Subject of Research: Safety of thermoprotective techniques during image-guided cryoablation and radiofrequency ablation of musculoskeletal tumors

Article Title: Too close for comfort? Assessing the impact of thermoprotective techniques in image-guided ablation of musculoskeletal tumors

Article References: Stokes, C., Ly, M., Tomasian, A., Imaoka, R., Vander Velde, T. L., Northrup, B. E., Cusworth, B., & Jennings, J. W. (2025). Too close for comfort? Assessing the impact of thermoprotective techniques in image-guided ablation of musculoskeletal tumors. CVIR Oncology, 1(1), Article 18. https://doi.org/10.1007/s44343-025-00014-2

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00014-2

Keywords: cryoablation, radiofrequency ablation, musculoskeletal tumors, thermoprotection, interventional radiology, spinal metastases, hydrodissection, neurophysiologic monitoring, pain palliation, interventional oncology, patient safety, image-guided ablation

The research, conducted at a single German center and published in CVIR Oncology, followed 13 consecutive patients who underwent percutaneous CT-guided cryoablation of histologically confirmed desmoid tumors between January 2019 and December 2024. Most were young women with tumors embedded in the rectus abdominis muscle of the abdominal wall, the classic setting for this rare disease, which strikes roughly two to four people per million each year. Twelve of the thirteen had already failed at least one line of systemic therapy, ranging from nonsteroidal anti-inflammatory drugs and hormonal agents to chemotherapy and, in one case, a gamma-secretase inhibitor.

Cryoablation destroys tissue by cycling it between extreme cold and thaw. In this study, interventional radiologists placed between 2 and 16 thin cryoprobes directly into each tumor under CT fluoroscopic guidance while the patient was under general anesthesia. A standardized double freeze-thaw protocol followed: two ten-minute freeze cycles separated by passive and active thawing phases. During each freeze, the growing ice ball is visible on CT as a sharply defined dark region, a unique advantage of cryoablation over heat-based ablation techniques, allowing operators to watch the lethal zone expand in real time and confirm it covers the tumor with at least a five-millimeter margin.

The critical technical challenge lies in what surrounds these tumors. Because most desmoids in this cohort sat in the abdominal wall, the bowel loops immediately behind the target were the structures most at risk of catastrophic freeze injury. The team deployed protective dissection techniques in 76.9 percent of procedures: hydrodissection with 5 percent dextrose solution in just over half the cases, CO₂ pneumodissection in two patients, and air dissection in one. In laparoscopically assisted cases, surgeons created capnoperitoneum and directly observed the ice ball from inside the peritoneal cavity, retracting probes by pre-planned distances between freeze cycles to sculpt an enlarged zone of destruction. Every patient’s skin was protected with injected fluid and a warm saline-filled glove.

What distinguishes this study from earlier cryoablation series is its measurement strategy. Rather than tracking overall tumor diameter with standard RECIST criteria, the investigators systematically quantified the enhancing tumor volume on contrast-enhanced MRI, using the ellipsoid formula to calculate viable, cellular tissue separately from the non-enhancing fibrotic residue that persists long after successful ablation. This distinction proved dramatic. At a median follow-up of 14.5 months, median viable tumor volume collapsed from 70.5 cubic centimeters to just 1.97 cubic centimeters, a 98.3 percent reduction with a large statistical effect size. Yet the median entire lesion volume remained 6.7 cubic centimeters, and in the most striking individual case a patient retained a 251-cubic-centimeter residual mass of which less than 2 percent was living tissue.

That discrepancy carries a direct clinical warning. Conventional size-based response criteria, which measure the whole lesion including dead fibrotic tissue, would classify many of these successfully treated patients as having only stable or partial disease, badly underestimating how thoroughly the tumor had been devitalized. Applying modified RECIST criteria, which evaluate only the enhancing component, the authors found six of twelve evaluable patients achieved complete response and six achieved partial response, for an objective response rate of 100 percent. No patient showed progression during follow-up.

Objective MRI signal analysis corroborated the volumetric findings. The T2 contrast-to-noise ratio, a quantitative measure of how brightly tumor tissue stands out from background noise on T2-weighted images, fell from a median of 146.9 at baseline to 19.5 at last follow-up, reflecting replacement of highly cellular tumor by avascular fibrosis and coagulative necrosis. T2 signal intensity relative to muscle also dropped significantly. These quantitative markers align with prior work showing that intermediate T2 signal combined with nodularity and enhancement predicts post-ablation growth, offering clinicians measurable indicators of durable local control.

Patients themselves reported substantial benefit: twelve of thirteen described improved symptoms. The safety record, however, was not flawless. One patient, notably the only one treated without any prior therapy, suffered a severe grade 3b complication after the protective dissection was discontinued at cryoprobe retrieval before the ice ball had fully thawed. The residual ice contacted adjacent bowel and skin, causing bowel wall necrosis, cutaneous frostbite, and an enterocutaneous fistula requiring surgical repair; the patient was lost to follow-up. The remaining twelve patients experienced no complications at all, and the overall 7.7 percent major complication rate sits within the 0 to 17 percent range reported across published desmoid cryoablation series.

The results compare favorably with landmark studies. The prospective CRYODESMO-01 trial reported an 86 percent nonprogression rate at twelve months and a 79 percent objective response rate, while a ten-year pediatric and young adult series documented symptom improvement in 90 percent of patients but tumor volume reductions exceeding 75 percent in only 43 percent. The authors caution that their exceptional figures likely reflect selection bias and the small sample size, and that a median follow-up of 14.5 months cannot capture recurrences appearing years later.

Nevertheless, the study delivers a clear message for the multidisciplinary management of desmoid tumors. Cryoablation, positioned as a second- or third-line option after systemic therapy fails, achieves near-complete elimination of viable tumor with meaningful symptom relief and objective, quantitative MRI evidence of tumor death. The practical implication for radiologists and oncologists alike is to differentiate viable from total lesion volume when interpreting post-ablation imaging: large areas of residual non-enhancing tissue should never be mistaken for treatment failure. Larger prospective trials with patient-reported outcomes and extended follow-up are now needed to cement enhancing volume-based assessment as the standard endpoint for this increasingly credible, minimally invasive treatment.

The biology underlying desmoid tumors helps explain why local destruction can be so effective despite the tumors’ infiltrative habits. Most sporadic cases harbor activating mutations in the CTNNB1 gene, which stabilizes beta-catenin and drives the Wnt signaling pathway that fuels fibroblast proliferation. A minority arise in patients with familial adenomatous polyposis, where germline APC mutations set the stage. Because these tumors rarely metastasize, controlling the local disease is essentially controlling the whole disease, which is why a technique that devitalizes the entire enhancing component can translate into durable clinical benefit.

The demographic pattern of the disease also deserves emphasis. Desmoid tumors show a striking predilection for young women, and pregnancy and the postpartum period are recognized risk factors, with estrogen thought to modulate tumor behavior in at least a subset of patients. This means many patients face decades of life ahead of them at diagnosis, making the avoidance of radical surgery with its high recurrence rates and functional morbidity particularly consequential. An abdominal wall tumor in a woman of childbearing age, for example, can compromise core strength, posture, and future pregnancies if treated with wide resection, whereas a percutaneous needle-based approach preserves the muscle envelope even if some fibrotic residue remains.

The shift toward active surveillance as a first step deserves further context. Longitudinal observational cohorts have shown that a substantial fraction of desmoid tumors, in some series approaching half, either regress spontaneously or remain stable without any intervention. This observation, formalized in consensus guidelines from the Desmoid Tumor Working Group, fundamentally changed the treatment algorithm: intervention, whether systemic therapy, radiation, surgery, or ablation, is now reserved for tumors that progress on surveillance or cause significant symptoms. The patients in the cryoablation study fit squarely into this modern paradigm, having been selected precisely because their disease demanded treatment after systemic options were exhausted or declined.

On the mechanistic side, cryoablation’s lethality depends on achieving sufficiently low temperatures throughout the target volume. Vascularized tissue dies reliably when cooled to roughly minus twenty to minus forty degrees Celsius, with ice crystal formation disrupting cell membranes, vascular stasis producing ischemia, and the slow thaw phase amplifying the injury. The double freeze-thaw protocol used here exploits this last phenomenon: the second cycle kills cells already sensitized by the first, and the freeze-thaw alternation damages the microvasculature more thoroughly than a single prolonged freeze. This is why the authors insisted on an ablation margin of at least five millimeters beyond the enhancing tumor boundary, since the lethal isotherm sits inside the visible edge of the ice ball.

The choice of 5 percent dextrose in water for hydrodissection is also deliberate rather than arbitrary. Isotonic saline conducts electrical current and would be hazardous with radiofrequency ablation, but for cryoablation the more relevant property is thermal: fluid placed between tumor and bowel acts as a physical and thermal buffer, pushing heat-rich structures out of the freeze zone. Dextrose solution also avoids the theoretical concern of saline’s higher thermal conductivity accelerating ice growth toward protected structures.

Finally, the emergence of gamma-secretase inhibitors, exemplified by nirogacestat’s regulatory approval based on randomized trial evidence, has added a systemic option that did not exist for most of the study period. How ablation and these targeted agents will be sequenced remains an open question, and head-to-head comparisons incorporating volumetric endpoints, patient-reported symptom scores, and cost-effectiveness analysis will be needed to define each therapy’s proper place in a disease whose natural history is as variable as its treatment options are expanding.

Subject of Research: Percutaneous CT-guided cryoablation of desmoid tumors with volumetric MRI outcome assessment

Article Title: Percutaneous CT-guided cryoablation of desmoid tumors: single-center experience with volumetric midterm outcome

Article References: Schaaf, M., Sattler, T., Spatz, J., Surwald, S., Schraut, J., & Jakobs, T. F. (2026). Percutaneous CT-guided cryoablation of desmoid tumors: single-center experience with volumetric midterm outcome. CVIR Oncology, 2(1), Article 22. https://doi.org/10.1007/s44343-026-00060-4

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00060-4

Keywords: desmoid tumor, cryoablation, aggressive fibromatosis, interventional radiology, CT-guided ablation, volumetric assessment, mRECIST, MRI, hydrodissection, soft tissue tumor, minimally invasive, local recurrence